In this slide show we highlight some of the top news on breast cancer in 2017, including long-term benefits of mammography, treatment advances, pregnancy in survivors, and more.
Breast Cancer Year in Review 2017
Developments in Breast Cancer 2017–2018: New Drugs, New Drug Classes—and the Prospect of More to Come
This interview provides perspective on developments in breast cancer treatment in 2017, as well as a preview of what we can expect to change in the treatment of breast cancer in 2018.
This article reviews the mechanisms of sexual dysfunction that occur after breast cancer, offers some practical guidance on how to discuss this effectively with patients, and reviews the data and recommendations for optimizing management.
COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease.
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences.
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.